1
|
Japanese encephalitis virus: Associated immune response and recent progress in vaccine development. Microb Pathog 2019; 136:103678. [DOI: 10.1016/j.micpath.2019.103678] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 08/19/2019] [Accepted: 08/19/2019] [Indexed: 11/17/2022]
|
2
|
Olayan E, El-Khadragy M, Mohamed AF, Mohamed AK, Shebl RI, Yehia HM. Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: In Vitro Study. BIOMED RESEARCH INTERNATIONAL 2019; 2019:4518163. [PMID: 31008105 PMCID: PMC6441502 DOI: 10.1155/2019/4518163] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 02/10/2019] [Indexed: 12/25/2022]
Abstract
Inactivation of rabies virus is essential for rabies vaccine preparation where the inactivating compound that is currently recommended for rabies vaccine preparation is β-propiolactone (β-PL). This compound is considered better than phenol and formalin but it is expensive and potentially carcinogenic. Data revealed that Ascorbic acid (AA) with cupric ions could yield complete and irreversible inactivation of rabies virus without adversely affecting its antigenicity. Additionally, the results of testing the vaccine potency with the selected inactivating compounds were comparable (P<0.05), and ED50 was higher than the recommended World Health Organization (WHO) limits. The use of HemaGel (plasma substitute) for testing vaccine stabilization was compared with the currently used vaccine stabilizers (human albumin and lactose). HemaGel yielded better stability than the other tested stabilizers. Monitoring of cellular and humoral immune responses indicated that both the total IgG level against rabies vaccine and the IFN and IL5 levels obtained with the HemaGel-stabilized vaccines were higher than those obtained with human albumin- and lactose-stabilized vaccine candidates.
Collapse
Affiliation(s)
- Ebtesam Olayan
- Chair Vaccines Research of Infectious Diseases, Faculty of Science, Zoology Department, King Saud University, Riyadh, Saudi Arabia
| | - Manal El-Khadragy
- Chair Vaccines Research of Infectious Diseases, Faculty of Science, Zoology Department, King Saud University, Riyadh, Saudi Arabia
- Zoology Department, College of Science, King Saud University, Riyadh, Saudi Arabia
- Department of Zoology and Entomology, Faculty of Science, Helwan University, Cairo, Egypt
| | - Aly Fahmy Mohamed
- Holding Company for Production of Sera, Vaccines and Drugs (VACSEA), Egypt
| | | | - Rania Ibrahim Shebl
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University (ACU), Cairo, Egypt
| | - Hany M. Yehia
- Department of Food Science and Nutrition, College of Food and Agricultural Sciences, King Saud University, Saudi Arabia
- Department of Food Science and Nutrition, Faculty of Home Economics, Helwan University, Egypt
| |
Collapse
|
3
|
Nami S, Mohammadi R, Vakili M, Khezripour K, Mirzaei H, Morovati H. Fungal vaccines, mechanism of actions and immunology: A comprehensive review. Biomed Pharmacother 2018; 109:333-344. [PMID: 30399567 DOI: 10.1016/j.biopha.2018.10.075] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 10/02/2018] [Accepted: 10/14/2018] [Indexed: 11/28/2022] Open
Abstract
Fungal infections include a wide range of opportunistic and invasive diseases. Two of four major fatal diseases in patients with human immunodeficiency virus (HIV) infection are related to the fungal infections, cryptococcosis, and pneumocystosis. Disseminated candidiasis and different clinical forms of aspergillosis annually impose expensive medical costs to governments and hospitalized patients and ultimately lead to high mortality rates. Therefore, urgent implementations are necessary to prevent the expansion of these diseases. Designing an effective vaccine is one of the most important approaches in this field. So far, numerous efforts have been carried out in developing an effective vaccine against fungal infections. Some of these challenges engaged in different stages of clinical trials but none of them could be approved by the United States Food and Drug Administration (FDA). Here, in addition to have a comprehensive overview on the data from studied vaccine programs, we will discuss the immunology response against fungal infections. Moreover, it will be attempted to clarify the underlying immune mechanisms of vaccines targeting different fungal infections that are crucial for designing an effective vaccination strategy.
Collapse
Affiliation(s)
- Sanam Nami
- Department of Medical Mycology and Parasitology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Rasoul Mohammadi
- Department of Medical Parasitology and Mycology, School of Medicine/Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mahshid Vakili
- Department of Medical Mycology and Parasitology/Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Kimia Khezripour
- Department of Pharmacotherapy, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hamed Mirzaei
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
| | - Hamid Morovati
- Department of Medical Mycology and Parasitology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
4
|
Martínez O, Bravo Cruz A, Santos S, Ramírez M, Miranda E, Shisler J, Otero M. Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge. Vaccine 2017. [PMID: 28629922 DOI: 10.1016/j.vaccine.2017.05.091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Smallpox is a disease caused by Variola virus (VARV). Although eradicated by WHO in 1980, the threat of using VARV on a bioterror attack has increased. The current smallpox vaccine ACAM2000, which consists of live vaccinia virus (VACV), causes complications in individuals with a compromised immune system or with previously reported skin diseases. Thus, a safer and efficacious vaccine needs to be developed. Previously, we reported that our virus-free DNA vaccine formulation, a pVAX1 plasmid encoding codon-optimized VACV A27L gene (pA27LOPT) with and without Imiquimod adjuvant, stimulates A27L-specific production of IFN-γ and increases humoral immunity 7days post-vaccination. Here, we investigated the immune response of our novel vaccine by measuring the frequency of splenocytes producing IFN-γ by ELISPOT, the TH1 and TH2 cytokine profiles, and humoral immune responses two weeks post-vaccination, when animals were challenged with VACV. In all assays, the A27-based DNA vaccine conferred protective immune responses. Specifically, two weeks after vaccination, mice were challenged intranasally with vaccinia virus, and viral titers in mouse lungs and ovaries were significantly lower in groups immunized with pA27LOPT and pA27LOPT+Imiquimod. These results demonstrate that our vaccine formulation decreases viral replication and dissemination in a virus-free DNA vaccine platform, and provides an alternative towards a safer an efficacious vaccine.
Collapse
Affiliation(s)
- Osmarie Martínez
- Department of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campus, School of Medicine, San Juan, PR 00936, United States
| | - Ariana Bravo Cruz
- Department of Microbiology, School of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign, IL 61801, United States
| | - Saritza Santos
- Department of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campus, School of Medicine, San Juan, PR 00936, United States
| | - Maite Ramírez
- Department of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campus, School of Medicine, San Juan, PR 00936, United States
| | - Eric Miranda
- Department of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campus, School of Medicine, San Juan, PR 00936, United States
| | - Joanna Shisler
- Department of Microbiology, School of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign, IL 61801, United States
| | - Miguel Otero
- Department of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campus, School of Medicine, San Juan, PR 00936, United States.
| |
Collapse
|
5
|
Russi R, García MI, Vignatti P, Veiga MF, Vazquez-Levin MH, Veaute C. Immune mediators associated to male infertility in a mouse model of DNA immunization with the sperm protease proacrosin. J Reprod Immunol 2016; 118:28-35. [DOI: 10.1016/j.jri.2016.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Revised: 08/02/2016] [Accepted: 08/15/2016] [Indexed: 11/16/2022]
|
6
|
Nahampun HN, Bosworth B, Cunnick J, Mogler M, Wang K. Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice. PLANT CELL REPORTS 2015; 34:969-80. [PMID: 25677970 DOI: 10.1007/s00299-015-1758-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2014] [Revised: 01/22/2015] [Accepted: 01/28/2015] [Indexed: 05/27/2023]
Abstract
Oral administration of maize-expressed H3N2 nucleoprotein induced antibody responses in mice showing the immunogenicity of plant-derived antigen and its potential to be utilized as a universal flu vaccine. Influenza A viruses cause influenza epidemics that are devastating to humans and livestock. The vaccine for influenza needs to be reformulated every year to match the circulating strains due to virus mutation. Influenza virus nucleoprotein (NP) is a multifunctional RNA-binding protein that is highly conserved among strains, making it a potential candidate for a universal vaccine. In this study, the NP gene of H3N2 swine origin influenza virus was expressed in maize endosperm. Twelve transgenic maize lines were generated and analyzed for recombinant NP (rNP) expression. Transcript analysis showed the main accumulation of rNP in seed. Protein level of rNP in T1 transgenic maize seeds ranged from 8.0 to 35 µg of NP/g of corn seed. The level increased up to 70 µg of NP/g in T3 seeds. A mouse study was performed to test the immunogenicity of one line of maize-derived rNP (MNP). Mice were immunized with MNP in a prime-boost design. Oral gavage administration showed that a humoral immune response was elicited in the mice treated with MNP indicating the immunogenicity of MNP. NP-specific antibody responses in the MNP group showed comparable antibody titer with the groups receiving positive controls such as Vero cell-derived NP (VNP) or alphavirus replicon particle-derived NP (ANP). Cytokine analysis showed antigen-specific stimulation of IL-4 cytokine elicited in splenocytes from mice treated with MNP further confirming a TH2 humoral immune response induced by MNP administration.
Collapse
Affiliation(s)
- Hartinio N Nahampun
- Interdepartmental Plant Biology Major, Iowa State University, Ames, IA, 50011-1010, USA
| | | | | | | | | |
Collapse
|
7
|
Martínez O, Miranda E, Ramírez M, Santos S, Rivera C, Vázquez L, Sánchez T, Tremblay RL, Ríos-Olivares E, Otero M. Immunomodulator-based enhancement of anti smallpox immune responses. PLoS One 2015; 10:e0123113. [PMID: 25875833 PMCID: PMC4395221 DOI: 10.1371/journal.pone.0123113] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 02/27/2015] [Indexed: 12/23/2022] Open
Abstract
Background The current live vaccinia virus vaccine used in the prevention of smallpox is contraindicated for millions of immune-compromised individuals. Although vaccination with the current smallpox vaccine produces protective immunity, it might result in mild to serious health complications for some vaccinees. Thus, there is a critical need for the production of a safe virus-free vaccine against smallpox that is available to everyone. For that reason, we investigated the impact of imiquimod and resiquimod (Toll-like receptors agonists), and the codon-usage optimization of the vaccinia virus A27L gene in the enhancement of the immune response, with intent of producing a safe, virus-free DNA vaccine coding for the A27 vaccinia virus protein. Methods We analyzed the cellular-immune response by measuring the IFN-γ production of splenocytes by ELISPOT, the humoral-immune responses measuring total IgG and IgG2a/IgG1 ratios by ELISA, and the TH1 and TH2 cytokine profiles by ELISA, in mice immunized with our vaccine formulation. Results The proposed vaccine formulation enhanced the A27L vaccine-mediated production of IFN-γ on mouse spleens, and increased the humoral immunity with a TH1-biased response. Also, our vaccine induced a TH1 cytokine milieu, which is important against viral infections. Conclusion These results support the efforts to find a new mechanism to enhance an immune response against smallpox, through the implementation of a safe, virus-free DNA vaccination platform.
Collapse
Affiliation(s)
- Osmarie Martínez
- Department of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
| | - Eric Miranda
- Department of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
- Department of Microbiology Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
| | - Maite Ramírez
- Department of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
| | - Saritza Santos
- Department of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
| | - Carlos Rivera
- Department Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico
| | - Luis Vázquez
- Department Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico
| | - Tomás Sánchez
- Department Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico
| | - Raymond L. Tremblay
- Department of Biology, University of Puerto Rico, Humacao, Puerto Rico
- Department of Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico
- Center for Applied Tropical Ecology and Conservation, University of Puerto Rico, Rio Piedras campus, San Juan, Puerto Rico
| | - Eddy Ríos-Olivares
- Department of Microbiology Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
| | - Miguel Otero
- Department of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
- * E-mail:
| |
Collapse
|
8
|
Guo XQ, Wang LQ, Qiao H, Yang XW, Yang MF, Chen HY. Enhancement of the immunogenicity of a porcine circovirus type 2 DNA vaccine by a recombinant plasmid coexpressing capsid protein and porcine interleukin-6 in mice. Microbiol Immunol 2015; 59:174-80. [DOI: 10.1111/1348-0421.12244] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 01/13/2015] [Accepted: 01/28/2015] [Indexed: 01/14/2023]
Affiliation(s)
- Xiao-Qing Guo
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Lin-Qing Wang
- Department of Life Science; Zhengzhou Normal University; Zhengzhou 450044 Henan Province China
| | - Han Qiao
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Xing-Wu Yang
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Ming-Fan Yang
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| | - Hong-Ying Chen
- College of Animal Science and Veterinary Medicine; Henan Agricultural University; 63 Nongye Road Zhengzhou 450002
| |
Collapse
|
9
|
Luo J, Yang J, Cheng Y, Li W, Yin TL, Xu WM, Zou YJ. Immunogenicity study of plasmid DNA encoding mouse cysteine-rich secretory protein-1 (mCRISP1) as a contraceptive vaccine. Am J Reprod Immunol 2012; 68:47-55. [PMID: 22429321 DOI: 10.1111/j.1600-0897.2012.01117.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Accepted: 02/03/2012] [Indexed: 11/28/2022] Open
Abstract
PROBLEM To examine the immunocontraceptive properties of the plasmid pcDNA-mCRISP1 and compare them to the corresponding recombinant mCRISP1 (r-mCRISP1). METHOD OF STUDY RT-PCR and indirect immunofluorescence were performed to observe the mCRISP1 protein expression in COS-7 cells. Three groups of mice received three injections of r-mCRISP1, pcDNA-mCRISP1 or pcDNA vector, respectively. ELISA and Western blot were used to examine the immune responses and immunoreactivity of antisera. Sperm-egg penetration assay was performed to examine the effect of anti-mCRISP1 antibodies in vitro fertilization of mouse oocytes. Fertility and mean litter size were analysed by natural mating. Histological analysis was carried out to look for potential immunopathologic effects of the antibodies. RESULTS COS-7 cells transfected with pcDNA-mCRISP1 present the expression of mCRISP1. Both r-mCRISP1 and pcDNA-mCRISP1 raised an immune response against r-mCRISP1 protein and native CRISP1 in mouse sperm. The titres of anti-mCRISP1 antibodies from DNA immunized mice were significantly lower than that of r-mCRISP1 immunized mice, but it lasted relatively longer. Male and female pcDNA-mCRISP1 injected animals presented a statistically significant reduction in their fertility with no signs of immunopathologic effects. CONCLUSION These studies demonstrated the feasibility of generating an immune response to mCRISP1 protein by DNA vaccine and pcDNA-mCRISP1 plasmid causing significant anti-fertility potential.
Collapse
Affiliation(s)
- Jin Luo
- Reproductive Medical Center, Renmin Hospital of Wuhan University, Wuhan, China
| | | | | | | | | | | | | |
Collapse
|
10
|
O'Hara DM, Theobald V, Egan AC, Usansky J, Krishna M, TerWee J, Maia M, Spriggs FP, Kenney J, Safavi A, Keefe J. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS JOURNAL 2012; 14:316-28. [PMID: 22415613 DOI: 10.1208/s12248-012-9334-9] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Accepted: 02/07/2012] [Indexed: 11/30/2022]
Abstract
Critical reagents are essential components of ligand binding assays (LBAs) and are utilized throughout the process of drug discovery, development, and post-marketing monitoring. Successful lifecycle management of LBA critical reagents minimizes assay performance problems caused by declining reagent activity and can mitigate the risk of delays during preclinical and clinical studies. Proactive reagent management assures adequate supply. It also assures that the quality of critical reagents is appropriate and consistent for the intended LBA use throughout all stages of the drug development process. This manuscript summarizes the key considerations for the generation, production, characterization, qualification, documentation, and management of critical reagents in LBAs, with recommendations for antibodies (monoclonal and polyclonal), engineered proteins, peptides, and their conjugates. Recommendations are given for each reagent type on basic and optional characterization profiles, expiration dates and storage temperatures, and investment in a knowledge database system. These recommendations represent a consensus among the authors and should be used to assist bioanalytical laboratories in the implementation of a best practices program for critical reagent life cycle management.
Collapse
Affiliation(s)
- Denise M O'Hara
- Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, One Burtt Road, Andover, Massachusetts 01810, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Choi SH, Kim KH. Potential of auxotrophic Edwardsiella tarda double-knockout mutant as a delivery vector for DNA vaccine in olive flounder (Paralichthys olivaceus). Vet Immunol Immunopathol 2012; 145:625-30. [DOI: 10.1016/j.vetimm.2012.01.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Revised: 12/29/2011] [Accepted: 01/16/2012] [Indexed: 10/14/2022]
|
12
|
Zhao F, Wang S, Zhang X, Gu W, Yu J, Liu S, Zeng T, Zhang Y, Wu Y. Protective efficacy of a Treponema pallidum Gpd DNA vaccine vectored by chitosan nanoparticles and fused with interleukin-2. Can J Microbiol 2012; 58:117-23. [PMID: 22260167 DOI: 10.1139/w11-115] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In the present study, immunomodulatory responses of a DNA vaccine constructed by fusing Treponema pallidum (Tp) glycerophosphodiester phosphodiesterase (Gpd) to interleukin-2 (IL-2) and using chitosan (CS) nanoparticles as vectors were investigated. New Zealand white rabbits were immunized by intramuscular inoculation of control DNAs, Tp Gpd DNA vaccine, or Gpd-IL-2 fusion DNA vaccine, which were vectored by CS nanoparticles. Levels of the anti-Gpd antibodies and levels of IL-2 and interferon-γ in rabbits were increased upon inoculation of Gpd-IL-2 fusion DNA vaccine, when compared with the inoculation with Gpd DNA vaccine, with CS vectoring increasing the effects. The Gpd-IL-2 fusion DNA vaccine efficiently enhanced the antigen-specific lymphocyte proliferative response. When the rabbits were challenged intradermally with 10(5) Tp (Nichols) spirochetes, the Gpd-IL-2 fusion DNA vaccine conferred better protection than the Gpd DNA vaccine (P < 0.05), as characterized by lower detectable amounts of dark field positive lesions (17.5%), lower ulcerative lesion scores (15%), and faster recovery. Individuals treated with the Tp Gpd-IL-2 fusion DNA vaccine vectored by CS nanoparticles had the lowest amounts of dark field positive lesions (10%) and ulcerations (5%) observed and the fastest recovery (42 days). These results indicate that the Gpd-IL-2 fusion DNA vaccine vectored by CS nanoparticles can efficiently induce Th1-dominant immune responses, improve protective efficacy against Tp spirochete infection, and effectively attenuate development of syphilitic lesions.
Collapse
Affiliation(s)
- Feijun Zhao
- Pathogenic Biology Institute, University of South China, Hengyang, People's Republic of China
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Chen HY, Zhang HY, Li XS, Cui BA, Wang SJ, Geng JW, Li K. Interleukin-18-mediated enhancement of the protective effect of an infectious laryngotracheitis virus glycoprotein B plasmid DNA vaccine in chickens. J Med Microbiol 2011; 60:110-116. [DOI: 10.1099/jmm.0.024109-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The immunogenicity of an infectious laryngotracheitis virus (ILTV) glycoprotein B (gB) plasmid DNA vaccine and the immunoregulatory activity of chicken interleukin-18 (IL-18) were investigated in a challenge model. Two recombinant plasmids, pcDNA3.1/gB (pgB) and pcDNA3.1/IL-18 (pIL-18), containing gB and IL-18 were constructed. Chickens were intramuscularly administered two immunizations 2 weeks apart, and challenged with the virulent CG strain of ILTV 2 weeks later. All animals vaccinated with pgB alone or with a combination of pgB plus pIL-18 developed a specific anti-ILTV ELISA antibody and splenocyte proliferation response. The ratios of CD4+ to CD8+ T lymphocytes in chickens immunized with pgB plus pIL-18 were significantly higher than in those immunized with pgB alone. Co-injection of pIL-18 significantly increased the production of gamma interferon and IL-2, indicating that IL-18 enhances the T helper 1-dominant immune response. Challenge experiments showed that the morbidity rate in the pgB group (25 %) was significantly higher than that in the pgB plus pIL-18 group (10 %). The mortality rates in the pgB and pgB plus pIL-18 groups were 10 and 0 %, respectively, and the corresponding protection rates were 60 and 80 %. These results indicate that IL-18 may be an effective adjuvant for an ILTV vaccine.
Collapse
Affiliation(s)
- Hong-Ying Chen
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| | - Hong-Ying Zhang
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| | - Xin-Sheng Li
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| | - Bao-An Cui
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| | - Shu-Juan Wang
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| | - Jing-Wei Geng
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| | - Kun Li
- College of Animal Science and Veterinary Medicine, Henan Agricultural University, Wenhua Road 95, 450002 Zhengzhou, Henan, PR China
| |
Collapse
|
14
|
Hiszczyńska-Sawicka E, Akhtar M, Kay GW, Holec-Gąsior L, Bickerstaffe R, Kur J, Stankiewicz M. The immune responses of sheep after DNA immunization with, Toxoplasma gondii MAG1 antigen—with and without co-expression of ovine interleukin 6. Vet Immunol Immunopathol 2010; 136:324-9. [DOI: 10.1016/j.vetimm.2010.03.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2009] [Revised: 03/16/2010] [Accepted: 03/22/2010] [Indexed: 01/24/2023]
|
15
|
Wan C, Yi L, Yang Z, Yang J, Shao H, Zhang C, Pan Z. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Vet Immunol Immunopathol 2010; 137:47-53. [PMID: 20466439 DOI: 10.1016/j.vetimm.2010.04.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2009] [Revised: 03/19/2010] [Accepted: 04/12/2010] [Indexed: 10/19/2022]
Abstract
To evaluate the effects of the Toll/interleukin-1 receptor domain-containing adaptor-inducing interferon-beta (TRIF) on immune responses induced by DNA vaccines, mice were immunized with the eukaryotic expression plasmid pcDNA/E2 encoding classical swine fever virus (CSFV) E2 alone or in combination with the TRIF genetic adjuvant. Immune responses were examined in immunized mice. Our data demonstrates that co-delivery of the DNA vaccine pcDNA/E2 with the TRIF adjuvant augmented specific humoral and cellular immune responses in a mouse model. Vaccination of pigs confirmed that the pcDNA/E2 in combination with TRIF conferred total protection against lethal challenge with highly virulent CSFV. We conclude that TRIF enhances the effects of the DNA vaccine against CSFV infection and could be used as a potential genetic adjuvant for DNA vaccines in large animal species.
Collapse
Affiliation(s)
- Chao Wan
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
| | | | | | | | | | | | | |
Collapse
|
16
|
Comparison of immune response in sheep immunized with DNA vaccine encoding Toxoplasma gondii GRA7 antigen in different adjuvant formulations. Exp Parasitol 2010; 124:365-72. [DOI: 10.1016/j.exppara.2009.11.015] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Revised: 10/27/2009] [Accepted: 11/25/2009] [Indexed: 11/21/2022]
|
17
|
Tan B, Wang H, Shang L, Yang T. Coadministration of chicken GM-CSF with a DNA vaccine expressing infectious bronchitis virus (IBV) S1 glycoprotein enhances the specific immune response and protects against IBV infection. Arch Virol 2009; 154:1117-24. [PMID: 19543689 DOI: 10.1007/s00705-009-0424-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2009] [Accepted: 06/04/2009] [Indexed: 10/20/2022]
Abstract
Various approaches have been developed to improve the efficacy of DNA vaccination, such as the use of plasmids expressing cytokines as molecular adjuvants. The purpose of the present study was to determine whether co-administration of a plasmid containing a chicken granulocyte-macrophage colony-stimulating factor (GM-CSF) gene and a plasmid containing the S1 gene of infectious bronchitis virus (IBV) could enhance the immune response and protection efficacy in chickens against challenge by virulent IBV. Plasmids carrying the S1 gene of IBV (pVAX-S1) and the chicken GM-CSF gene (pVAX-chGM-CSF) were constructed. Seven-day-old chickens were injected intramuscularly with pVAX-S1, pVAX-chGM-CSF, or both and boosted 2 weeks later. Chickens were challenged with virulent IBV at 3 weeks after the booster immunization and observed for 2 weeks. The results showed that co-administration of pVAX-chGM-CSF led to a significant enhancement of humoral and cellular responses over that of vaccination with pVAX-S1 alone. In addition, vaccination with pVAX-chGM-CSF and pVAX-S1 provided 86.7% protection (13/15) against IBV challenge. In contrast, only 73.3% of the chickens were protected against IBV challenge by pVAX-S1 vaccination alone. These results strongly indicate that chGM-CSF can be used as a molecular adjuvant to enhance the protective immunity induced by an IBV-specific DNA vaccine.
Collapse
Affiliation(s)
- Bing Tan
- Sichuan Agricultural University, Yaan, People's Republic of China
| | | | | | | |
Collapse
|
18
|
An G, Huang TH, Wang DG, Xie QD, Ma L, Chen DY. In vitro and in vivo studies evaluating recombinant plasmid pCXN2-mIzumo as a potential immunocontraceptive antigen. Am J Reprod Immunol 2009; 61:227-35. [PMID: 19239425 DOI: 10.1111/j.1600-0897.2009.00685.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PROBLEMS Study on feasibility of pCXN2-mIzumo as a potential immunocontraceptive antigen. METHOD OF STUDY Two groups of mice received 100 microg/mouse plasmids of pCXN2-mIzumo and pCXN2 respectively. RT-PCR Immunofluorescence assay and ELISA were performed to observe pCXN2-mIzumo expression and antibody response in the inoculated mice. Sperm penetration assay and animal mating were employed to detect differences of in vitro fertilization (IVF) rate and mean litter size between the experimental and control groups. RESULTS Izumo cDNA positive bands were detected in sample from mice immunized with pCXN2-mIzumo. IgG response started to rise at 2 weeks after first boost and reached the highest antibody titers at 2 weeks after third boost of immunization with pCXN2-mIzumo in the experimental mice. In vitro fertilization rate in the experimental group (11.57%) was significantly lower than that in control (36.60%). Significant difference of mean litter size between female experimental and control groups was observed, and there was significant negative correlation between individual anti-serum titers and litter size (r = -0.308, P < 0.05). CONCLUSION pCXN2-mIzumo plasmid possesses appreciable anti-fertility potential.
Collapse
Affiliation(s)
- Gang An
- Research Center for Reproductive Medicine, Shantou University Medical College, Shantou, Guangdong, China
| | | | | | | | | | | |
Collapse
|
19
|
Abstract
BACKGROUND Multiple sclerosis (MS) is a disease in which safety is of paramount importance when developing a potential therapeutic. Antigen-specific treatments provide a method for achieving efficacy while maintaining safety. DNA vaccines are one such form of treatment that have been tested in clinical trials OBJECTIVE To determine if a DNA vaccine is a viable method of antigen-specific treatment of MS. RESULTS/CONCLUSION Phase I and II trials of BHT-3009, a DNA vaccine encoding myelin basic protein, demonstrated that it was safe, well-tolerated, and caused antigen-specific immune tolerance. BHT-3009 showed efficacy in reducing brain lesion activity as well as clinical relapses in patients that were immunologically active at baseline. BHT-3009 is a promising therapy in development for MS, and may prove to be one of the first antigen-specific treatments for this disease.
Collapse
Affiliation(s)
- Hideki Garren
- Stanford University, Department of Neurology and Neurological Sciences, Stanford, CA, USA.
| |
Collapse
|
20
|
Humar M, Maurer M, Azemar M, Groner B. DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis. J Cancer Res Clin Oncol 2008; 135:567-80. [DOI: 10.1007/s00432-008-0491-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2008] [Accepted: 09/18/2008] [Indexed: 10/21/2022]
|
21
|
Lin CC, Yen MC, Lin CM, Huang SS, Yang HJ, Chow NH, Lai MD. Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 2008; 10:679-89. [PMID: 18324638 DOI: 10.1002/jgm.1183] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND DNA vaccine is a new and powerful approach to generate immunological responses against infectious disease and cancer. The T helper type (Th)1 immune response is usually required for generating effective anti-tumor responses. A microparticulate bombardment system can induce an immune response using very low amounts of DNA. Using nozzle aerodynamics, a low pressure gene gun has been developed to decrease the noise associated with high pressure gene guns. Particles are propelled by supersonic flow through this novel nozzle. To test whether this gun could inoculate a DNA vaccine that stimulates an anti-tumor Th1 immune response, we examined the effect of direct delivery of naked DNA (i.e. without any carrier) on the anti-tumor immune response of mice. METHODS The luciferase reporter plasmid DNA was delivered using a low-pressure biolistic device and expressed in C3H/HeN, BALB/c, and C57BL/6 mice. RESULTS Plasmid DNA expression was mainly in the epidermis. Noncarrier naked neu DNA vaccine and gold particle-coated neu DNA vaccine (at 1 microg per mouse) had similar anti-tumor effects in C3H mice. However, cytokine profile examination showed the Th1-bias of the response induced by naked DNA vaccine and the Th2-bias of the response induced by coated DNA vaccine. CONCLUSIONS A shift in the immune response to favour enhanced tumor rejection can be achieved by skin delivery of naked DNA vaccine.
Collapse
Affiliation(s)
- Chi-Chen Lin
- Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | | | | | | | | | | | | |
Collapse
|
22
|
Guzel AI, Kasap H, Tuncer I, Ozgunen K, Sertdemir Y, Kasap M, Ozcan N, Yilmaz MB, Pazarbasi A. Suppression of the Tumorigenicity of B-16V Melanoma Cells via Lysozyme Gene. Cancer Biother Radiopharm 2008; 23:603-8. [DOI: 10.1089/cbr.2008.0516] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Ali I. Guzel
- Department of Medical Biology and Genetics, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Halil Kasap
- Department of Medical Biology and Genetics, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Ilhan Tuncer
- Department of Pathology, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Kerem Ozgunen
- Department of Physiology, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Yasar Sertdemir
- Department of Biostatistics, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Mulkiye Kasap
- Department of Medical Biology and Genetics, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Numan Ozcan
- Department of Faculty of Agriculture, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Mehmet B. Yilmaz
- Department of Medical Biology and Genetics, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| | - Ayfer Pazarbasi
- Department of Medical Biology and Genetics, Department of Biometry and Genetics, Faculty of Medicine Cukurova University, Adana, Turkey
| |
Collapse
|
23
|
Kong X, Hellermann GR, Zhang W, Jena P, Kumar M, Behera A, Behera S, Lockey R, Mohapatra SS. Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses. Allergy Asthma Clin Immunol 2008; 4:95-105. [PMID: 20525130 PMCID: PMC2868869 DOI: 10.1186/1710-1492-4-3-95] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
The use of chitosan nanoparticles as carriers for expression plasmids represents a major improvement in gene expression technology. We demonstrated previously that treatment with chitosan interferon-γ (IFN-γ) plasmid deoxyribonucleic acid (DNA) nanoparticles (chitosan interferon-γ nanogene [CIN]) led to in situ production of IFN-γ and a reduction in inflammation and airway reactivity in mice, but the mechanism underlying the immunomodulatory effects of CIN remains unclear. In this report, the effect of CIN treatment on the immune responses of CD8+ T cells and dendritic cells was examined in a BALB/c mouse model of ovalbumin (OVA)-induced allergic asthma. OT1 mice (OVA-T cell receptor [TCR] transgenic) were also used to test the effects of CIN on OVA-specific CD8+ T cells. CIN treatment caused a reduction in IFN-γ production in a subpopulation of OVA-specific CD8+ T cells cultured in vitro in the presence of OVA. CIN also reduced apoptosis of the CD8+ T cells. Examination of dendritic cells from lung and lymph nodes indicated that CIN treatment decreased their antigen-presenting activity, as evident from the reduction in CD80 and CD86 expression. Furthermore, CIN treatment significantly decreased the number of CD11c+b+ dendritic cells in lymph nodes, suggesting that endogenous IFN-γ expression may immunomodulate dendritic cell migration and activation. CIN therapy results in a reduction in proinflammatory CD8+ T cells and decreases the number and antigen-presenting activity of dendritic cells.
Collapse
Affiliation(s)
- Xiaoyuan Kong
- Division of Allergy and Immunology, Culverhouse Airway Disease Research and Nanomedicine Center, University of South Florida College of Medicine, Tampa, FL
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Arcuri M, Cappelletti M, Zampaglione I, Aurisicchio L, Nicosia A, Ciliberto G, Fattori E. Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. J Gene Med 2008; 10:1048-54. [DOI: 10.1002/jgm.1217] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
25
|
|
26
|
Jiang W, Ren L, Jin N. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-α. J Virol Methods 2007; 146:266-73. [PMID: 17868910 DOI: 10.1016/j.jviromet.2007.07.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2007] [Revised: 06/12/2007] [Accepted: 07/10/2007] [Indexed: 10/22/2022]
Abstract
Numerous strategies have been employed in an attempt to improve the immunogenicity and efficacy of nucleic acid vaccines. In the present study, the immunogenicity in the induction of humoral and cellular immune responses to HIV-1 DNA vaccine expressing a chimeric gene of gag and gp120 and the adjuvant effect of IFN-alpha on HIV-1 DNA vaccine were studied in a murine model. The DNA vaccine plasmid pVAX1-gag-gp120 and eukaryotic expression plasmid pVAX1-IFN were constructed by inserting the chimeric gene of gag and gp120 of HIV-1 and IFN-alpha into the downstream of CMV promoter of eukaryotic expression vector pVAX1, respectively. In vitro expression detected by RT-PCR and Western blotting showed that the genes of interest could be expressed in transfected HeLa cells. After BALB/c mice were immunized by three intramuscular inoculations of the HIV-1 DNA vaccine plasmids alone or in combination with IFN-alpha expression plasmids, the different levels of anti-HIV-1 humoral and cellular responses were measured comparable to the control groups immunized with pVAX1-IFN, parent plasmid pVAX1 or PBS. The percentage of CD3+CD4+ and CD3+CD8+ subgroups of spleen T lymphocytes and the specific cytotoxicity activities of splenic CTLs in the coinoculation group were significantly higher than those in the separate inoculation group, and an enhancement of antibody response was also observed in the coinoculation group compared with the separate inoculation group. Take together, coadministration of HIV-1 DNA vaccine plasmids and IFN-alpha expression plasmids can elicit stronger humoral and cellular immune responses in mice than HIV-1 DNA vaccine plasmids alone, and IFN-alpha can be an effective immunological adjuvant in DNA vaccination against HIV-1.
Collapse
Affiliation(s)
- Wenzheng Jiang
- Genetic Engineering Key Laboratory of PLA, The Eleventh Institute of Academy of Military Medical Sciences of PLA, Changchun 130062, People's Republic of China
| | | | | |
Collapse
|
27
|
Nascimento EJM, Amorim RV, Cavalcanti A, Alves VF, Nakazawa M, Pereira VRA, Lucena-Silva N. Assessment of a DNA vaccine encoding an anchored-glycosylphosphatidylinositol tegumental antigen complexed to protamine sulphate on immunoprotection against murine schistosomiasis. Mem Inst Oswaldo Cruz 2007; 102:21-7. [PMID: 17293994 DOI: 10.1590/s0074-02762007000100003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2006] [Accepted: 11/29/2006] [Indexed: 11/22/2022] Open
Abstract
Protamine sulphate/DNA complexes have been shown to protect DNA from DNase digestion in a lipid system for gene transfer. A DNA-based vaccine complexed to protamine sulphate was used to induce an immune response against Schistosoma mansoni anchored-glycosylphosphatidylinositol tegumental antigen in BALB/c mice. The protection elicited ranged from 33 to 44%. The spectrum of the elicited immune response induced by the vaccine formulation without protamine was characterized by a high level of IgG (IgG1> IgG2a). Protamine sulphate added to the DNA vaccine formulation retained the green fluorescent protein encoding-plasmid longer in muscle and spleen. The experiments in vivo showed that under protamine sulphate effect, the scope of protection remained unchanged, but a modulation in antibody production (IgG1= IgG2a) was observed.
Collapse
|
28
|
Kaneda T, Honda A, Hakozaki A, Fuse T, Muto A, Yoshida T. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology 2007; 148:2335-44. [PMID: 17255207 DOI: 10.1210/en.2006-1077] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In Graves' disease, the overstimulation of the thyroid gland and hyperthyroidism are caused by autoantibodies directed against the TSH receptor (TSHR) that mimics the action of TSH. The establishment of an animal model is an important step to study the pathophysiology of autoimmune hyperthyroidism and for immunological analysis. In this study, we adopted the technique of electroporation (EP) for genetic immunization to achieve considerable enhancement of in vivo human TSHR (hTSHR) expression and efficient induction of hyperthyroidism in mice. In a preliminary study using beta-galactosidase (beta-gal) expression vectors, beta-gal introduced into the muscle by EP showed over 40-fold higher enzymatic activity than that introduced via previous direct gene transfer methods. The sustained hTSHR mRNA expression derived from cDNA transferred by EP was detectable in muscle tissue for at least 2 wk by RT-PCR. Based on these results, we induced hyperthyroidism via two expression vectors inserted with hTSHR or hTSHR289His cDNA. Consequently, 12.0-31.8% BALB/c mice immunized with hTSHR and 79.2-95.7% immunized with hTSHR289His showed high total T(4) levels due to the TSHR-stimulating antibody after three to four times repeated immunization by EP, and thyroid follicles of which were hyperplastic and had highly irregular epithelium. Moreover, TSHR-stimulating antibody surprisingly persisted more than 8 months after the last immunization. These results demonstrate that genetic immunization by in vivo EP is more efficient than previous procedures, and that it is useful for delineating the pathophysiology of Graves' disease.
Collapse
Affiliation(s)
- Toshio Kaneda
- Department of Pathophysiology, Hoshi University, Shinagawa, Tokyo 142-8501, Japan
| | | | | | | | | | | |
Collapse
|
29
|
Maue AC, Waters WR, Palmer MV, Nonnecke BJ, Minion FC, Brown WC, Norimine J, Foote MR, Scherer CFC, Estes DM. An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis. Vaccine 2007; 25:4735-46. [PMID: 17499400 DOI: 10.1016/j.vaccine.2007.03.052] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Revised: 03/24/2007] [Accepted: 03/30/2007] [Indexed: 12/16/2022]
Abstract
The potency of genetic immunization observed in the mouse has demonstrated the utility of DNA vaccines to induce cell-mediated and humoral immune responses. However, it has been relatively difficult to generate comparable responses in non-rodent species. The use of molecular adjuvants may increase the magnitude of these suboptimal responses. In this study, we demonstrate that the co-administration of plasmid-encoded GM-CSF and CD80/CD86 with a novel ESAT-6:CFP10 DNA vaccine against bovine tuberculosis enhances antigen-specific cell-mediated immune responses. ESAT-6:CFP10+GM-CSF+CD80/CD86 DNA vaccinated animals exhibited significant (p<0.01) antigen-specific proliferative responses compared to other DNA vaccinates. Increased expression (p< or =0.05) of CD25 on PBMC from ESAT-6:CFP10+GM-CSF+CD80/CD86 DNA vaccinates was associated with increased proliferation, as compared to control DNA vaccinates. Significant (p<0.05) numbers of ESAT-6:CFP10-specific IFN-gamma producing cells were evident from all ESAT-6:CFP10 DNA vaccinated animals compared to control DNA vaccinates. However, the greatest increase in IFN-gamma producing cells was from animals vaccinated with ESAT-6:CFP10+GM-CSF+CD80/CD86 DNA. In a low-dose aerosol challenge trial, calves vaccinated as neonates with Mycobacterium bovis BCG and ESAT-6:CFP10+GM-CSF+CD80/CD86 DNA exhibited decreased lesion severity in the lung and lung-associated lymph nodes following viruluent M. bovis challenge compared to other vaccinated animals or non-vaccinated controls. These data suggest that a combined vaccine regimen of M. bovis BCG and a candidate ESAT-6:CFP10 DNA vaccine may offer greater protection against tuberculosis in cattle than vaccination with BCG alone.
Collapse
Affiliation(s)
- Alexander C Maue
- Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65211, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Brulet JM, Maudoux F, Thomas S, Thielemans K, Burny A, Leo O, Bex F, Hallez S. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Eur J Immunol 2007; 37:376-84. [PMID: 17274002 DOI: 10.1002/eji.200636233] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Human papillomavirus type 16 is commonly implicated in cervical cancers. The viral genome encodes potential targets like the oncoprotein E7, expressed in transformed cells but thought to represent a poorly immunogenic antigen. We describe in this work a DNA-based vaccination protocol aimed at inducing an efficient anti-E7 immune response in vivo. Plasmids allowing the expression of the E7 protein in distinct cellular compartments were generated and assayed in an in vivo model of tumor growth. Our data demonstrate that mice vaccinated with a plasmid encoding for an E7 protein fused to a domain of the MHC class II-associated invariant chain (IiE7) were protected against tumor challenge. Mice immunized against an ubiquitinated form of E7 (Ub(Ala)E7) failed to control tumor growth. Protection induced by IiE7 was correlated with the development of CD8+ CTL and required the presence of CD4+ cells. In vitro studies confirmed that the IiE7 fusion protein was expressed at high levels in the endosomal compartment of transfected cells, while the natural and the ubiquitin-modified form of E7 were mainly nuclear. The present study suggests that an efficient anti-tumor response can be induced in vivo by DNA constructs encoding for E7 protein forms localizing at the endosomal compartment.
Collapse
Affiliation(s)
- Jean-Marc Brulet
- Laboratory of Chemical Biology, Institut de Biologie et de Médecine Moléculaires, Université Libre de Bruxelles, Gosselies, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Cutler JE, Deepe GS, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5:13-28. [PMID: 17160002 PMCID: PMC2214303 DOI: 10.1038/nrmicro1537] [Citation(s) in RCA: 160] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The dramatic increase in fungal diseases in recent years can be attributed to the increased aggressiveness of medical therapy and other human activities. Immunosuppressed patients are at risk of contracting fungal diseases in healthcare settings and from natural environments. Increased prescribing of antifungals has led to the emergence of resistant fungi, resulting in treatment challenges. These concerns, together with the elucidation of the mechanisms of protective immunity against fungal diseases, have renewed interest in the development of vaccines against the mycoses. Most research has used murine models of human disease and, as we review in this article, the knowledge gained from these studies has advanced to the point where the development of vaccines targeting human fungal pathogens is now a realistic and achievable goal.
Collapse
Affiliation(s)
- Jim E. Cutler
- Departments of Pediatrics and Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences, and Research Institute for Children at Children’s Hospital, New Orleans, Louisiana, 70118 USA
| | - George S. Deepe
- Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, 45267–0560 USA
| | - Bruce S. Klein
- Departments of Pediatrics, Internal Medicine, and Medical Microbiology and Immunology and the University of Wisconsin Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 53792 USA
| |
Collapse
|
32
|
Yoshikawa T, Okada N, Nakagawa S. Fusogenic liposomes and their suitability for gene delivery. ACTA ACUST UNITED AC 2006. [DOI: 10.2217/17460875.1.6.735] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
33
|
Abstract
Significant progress made in the field of tumor immunology by the characterization of a large number of tumor antigens, and the better understanding of the mechanisms preventing immune responses to malignancies has led to the extensive study of cancer immunization approaches such as DNA vaccines encoding tumor antigens. This article reviews major aspects of DNA immunization in cancer. It gives a brief history and then discusses the proposed mechanism of action, preclinical and clinical studies, and methods of enhancing the immune responses induced by DNA vaccines.
Collapse
Affiliation(s)
- Rodica Stan
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | |
Collapse
|
34
|
Jiang W, Jin N, Cui S, Li Z, Zhang L, Wang H, Han W. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector. J Virol Methods 2006; 136:1-7. [PMID: 16793146 DOI: 10.1016/j.jviromet.2006.01.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2005] [Revised: 01/26/2006] [Accepted: 01/31/2006] [Indexed: 11/15/2022]
Abstract
DNA vaccines have a demonstrated ability to induce humoral and cellular immune responses in animal models and humans. To analyze the immunogenicity of HIV-1 DNA vaccine which expressing the chimeric gene gag-gp120 of Chinese prevalent HIV-1 strain and the immunoregulatory activity of IL-6, DNA vaccine plasmid pVAX1-gag-gp120 and eukaryotic expression plasmid pVAX1-IL6 were constructed and the expression in vitro was detected by RT-PCR and Western blotting, the results showed that the gene of interest expressed in the transfected HeLa cells. To explore the immune response in mice coinoculated with HIV-1 DNA vaccine and IL-6 expression plasmid, BALB/c mice were injected i.m. with eukaryotic expression plasmid pVAX1-IL6 and DNA vaccine plasmid pVAX1-gag-gp120. The specific humoral and cellular immunity in mice could be induced by inoculating separately HIV-1 DNA vaccine plasmid or coinoculating with IL-6 expression plasmid, and the specific killing activities of spleen CTL and the level of serum antibodies in the coinoculation group were significantly higher than those in the separate inoculation group. These results strongly support the use of IL-6 as a cytokine adjuvant in DNA vaccination.
Collapse
Affiliation(s)
- Wenzheng Jiang
- School of Life Science, East China Normal University, Shanghai 200062, PR China.
| | | | | | | | | | | | | |
Collapse
|
35
|
Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses 2006; 22:667-77. [PMID: 16831091 DOI: 10.1089/aid.2006.22.667] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
A multiHIV fusion gene expressing an antigenic fusion protein composed of regulatory HIV-1 proteins Rev, Nef, and Tat, as well as Gag p17/p24 and a stretch of 11 cytotoxic T lymphocyte (CTL) epitope clusters from Pol and Env, was cloned into a novel DNA vector named the Gene Transport Unit (GTU). A mouse H-2(d)-restricted HIV-1 gp120 epitope (RGPGRAFVTI) was cloned into the fusion gene as well. In addition to the HIV- 1 genes the GTU codes for a nuclear anchoring protein (bovine papilloma virus E2), ensuring the long maintenance of the vector and a high expression level of the selected immunogens. BALB/c mice were immunized with the GTU-MultiHIV DNA construct by different routes and regimens of immunization to assess the immunogenicity of the DNA vaccine in vivo. Mice developed strong CD8(+) CTL responses to HIV-1 Env and Gag measured by an ELISPOT-IFN-gamma assay and chromium release assay. In addition, T cell responses to regulatory proteins Rev, Nef, and Tat were induced. Antibody responses were detected to each of the HIV antigens encoded by the DNA construct. Minimal doses of the GTU-MultiHIV DNA delivered by gene gun were potent in inducing significant HIV-specific CTL responses. The equivalent doses of the conventional plasmid expressing MultiHIV DNA delivered by gene gun failed to do so. An ideal DNA vaccine should yield high expression of the viral antigens for a prolonged period of time, and expression of the multiple viral antigens is probably required for the induction of a broad and protective immune response. The GTU-MultiHIV DNA vaccine described is a good vaccine candidate that meets the above criteria.
Collapse
MESH Headings
- AIDS Vaccines/genetics
- AIDS Vaccines/immunology
- Animals
- Antibodies, Antinuclear/immunology
- COS Cells
- Chlorocebus aethiops
- DNA-Binding Proteins/immunology
- Female
- Gene Products, gag/immunology
- Gene Products, nef/immunology
- Gene Products, rev/immunology
- Gene Products, tat/immunology
- HIV-1/immunology
- Humans
- Injections, Intramuscular
- Jurkat Cells
- Mice
- Mice, Inbred BALB C
- Plasmids/genetics
- Plasmids/immunology
- T-Lymphocytes/immunology
- Vaccines, DNA/genetics
- Vaccines, DNA/immunology
- Viral Proteins/immunology
- nef Gene Products, Human Immunodeficiency Virus
- rev Gene Products, Human Immunodeficiency Virus
- tat Gene Products, Human Immunodeficiency Virus
Collapse
|
36
|
Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol 2006; 18:678-88. [PMID: 16359234 DOI: 10.1089/vim.2005.18.678] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The correlate of protection in human immunodeficiency virus (HIV) infection is not known, but preclinical and clinical studies support the involvement of both antibodies and cellular immunity. In addition, the existence of multiple HIV clades makes HIV vaccine design especially challenging. We have constructed a vaccine platform with an HIV-1 subtype B DNA immunogen expressing full length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clusters from the env and pol regions. Furthermore, this platform has been extended to three additional plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH ancestral sequences. Immunogenicity in BALB/c mice, by gene gun or intramuscular delivery, revealed strong IFN-gamma production in response to in vitro re-stimulation with a H-2d restricted gag peptide (AMQMLKETI) or even stronger toward an env epitope (RGPGRAFVTI). Weak humoral immunity was detected. Gene gun immunization with a cocktail of all four plasmids induced pre-challenge cellular immunity in C57Bl6/A2.01 mice and subsequently a robust frequency of protection (11/12 animals) after experimental challenge with subtype A or B HIV-1/Murine Leukemia Virus (HIV-1/MuLV). The cross-clade protection observed in this challenge experiment demonstrates that these multigene/multiepitope HIV DNA immunogens are likely to be potent immunogens also against the HIV-infection of human beings.
Collapse
MESH Headings
- AIDS Vaccines/administration & dosage
- AIDS Vaccines/genetics
- AIDS Vaccines/immunology
- Animals
- Consensus Sequence
- Disease Models, Animal
- Epitopes/genetics
- Epitopes/immunology
- Female
- Gene Products, gag/genetics
- Gene Products, gag/immunology
- Gene Products, nef/genetics
- Gene Products, nef/immunology
- Gene Products, pol/genetics
- Gene Products, pol/immunology
- Gene Products, rev/genetics
- Gene Products, rev/immunology
- Gene Products, tat/genetics
- Gene Products, tat/immunology
- HIV Antibodies/blood
- HIV Envelope Protein gp160/genetics
- HIV Envelope Protein gp160/immunology
- HIV Infections/immunology
- HIV Infections/prevention & control
- HIV Infections/virology
- HIV-1/genetics
- HIV-1/immunology
- Interferon-gamma/biosynthesis
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/genetics
- Vaccines, DNA/immunology
- nef Gene Products, Human Immunodeficiency Virus
- pol Gene Products, Human Immunodeficiency Virus
- rev Gene Products, Human Immunodeficiency Virus
- tat Gene Products, Human Immunodeficiency Virus
Collapse
|
37
|
Ivanovska N, Tchorbanov A, Prechl J, Maximova V, Voynova E, Vassilev TL. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus. Vaccine 2006; 24:1830-7. [PMID: 16289708 DOI: 10.1016/j.vaccine.2005.10.029] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2005] [Revised: 10/05/2005] [Accepted: 10/13/2005] [Indexed: 11/20/2022]
Abstract
Killed viral vaccines are known to induce primarily antibody responses. By contrast DNA vaccination using naked DNA encoding viral antigens induces both humoral and cellular immune responses. Various approaches have been used to construct DNA vaccines with build-in adjuvanticity. We hypothesized that sequences encoding a common epitope of influenza A virus hemagglutinin jointed to sequences encoding a single-chain variable fragment (scFv) antibody fragment to a costimulatory B cell surface receptor would result in the in vivo expression of a chimeric viral peptide with increased immunogenicity. Such a hybrid DNA molecule was constructed by us, encoding a T and B cell epitope-containing influenza hemagglutinin peptide and a scFv antibody fragment binding to mouse complement receptors I and II (CR1 and CR2). A single immunization with a plasmid containing the described construct induced a strong anti-influenza cytotoxic response lasting for more than six months and a weak antibody response.
Collapse
MESH Headings
- Adjuvants, Immunologic
- Animals
- Antibodies, Viral/blood
- Cytotoxicity, Immunologic
- Enzyme-Linked Immunosorbent Assay
- Female
- Hemagglutination Inhibition Tests
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Immunoglobulin G/blood
- Immunoglobulin M/blood
- Immunoglobulin Variable Region/genetics
- Influenza A virus/immunology
- Influenza Vaccines/immunology
- Mice
- Mice, Inbred BALB C
- Receptors, Complement/immunology
- Receptors, Complement 3d/immunology
- T-Lymphocytes, Cytotoxic/immunology
- Vaccination
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/genetics
- Vaccines, DNA/immunology
Collapse
Affiliation(s)
- Nina Ivanovska
- Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
| | | | | | | | | | | |
Collapse
|
38
|
Summers C, Dewar P, van der Molen R, Cousens C, Salvatori D, Sharp JM, Griffiths DJ, Norval M. Jaagsiekte sheep retrovirus-specific immune responses induced by vaccination: A comparison of immunisation strategies. Vaccine 2006; 24:1821-9. [PMID: 16289765 DOI: 10.1016/j.vaccine.2005.10.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2005] [Revised: 09/08/2005] [Accepted: 10/13/2005] [Indexed: 12/31/2022]
Abstract
Jaagsiekte sheep retrovirus (JSRV) is the aetiological agent of ovine pulmonary adenocarcinoma (OPA). No JSRV-specific immunological responses have been detected in clinical cases of OPA or in experimentally infected lambs. The aim of the present study was to induce immune responses in sheep against JSRV proteins using several immunisation strategies. The vaccines were administered subcutaneously and intradermally, or intranasally, in adjuvant. Antibodies were measured by ELISA and immunoblotting, and T cell responses by lymphoproliferation assay. Antibodies specific for JSRV-capsid protein were induced by inoculation of recombinant proteins in adjuvant, and transient JSRV-specific T cell responses by intranasal inoculation with inactivated virus. These results will help in the design of a protective vaccine against JSRV infection and the development of OPA.
Collapse
MESH Headings
- Adjuvants, Immunologic
- Administration, Intranasal
- Animals
- Antibodies, Viral/blood
- Blotting, Western
- Enzyme-Linked Immunosorbent Assay
- Freund's Adjuvant/administration & dosage
- Injections, Intradermal
- Injections, Subcutaneous
- Jaagsiekte sheep retrovirus/immunology
- Lipids/administration & dosage
- Lymphocyte Activation
- Pulmonary Adenomatosis, Ovine/prevention & control
- Sheep
- T-Lymphocytes/immunology
- Vaccination/methods
- Vaccines, Subunit/administration & dosage
- Vaccines, Subunit/genetics
- Vaccines, Subunit/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
- Viral Proteins/administration & dosage
- Viral Proteins/genetics
- Viral Proteins/immunology
Collapse
|
39
|
Williams JA, Luke J, Johnson L, Hodgson C. pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids. Vaccine 2005; 24:4671-6. [PMID: 16448726 DOI: 10.1016/j.vaccine.2005.08.033] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
DNA vaccines have the potential to provide a safe route for protective immunity to neoplasms and infectious agents. However, current DNA vaccine plasmids are not optimal with additional non-essential DNA, nor do they facilitate controlled or flexible targeting of antigens to various intracellular destinations. A family of DNA vaccine vectors, optimized and minimized to comply with FDA guidelines regarding content and elimination of extraneous materials, was constructed. The resulting vectors are much smaller than existing vectors, drive higher levels of target gene expression, facilitate high throughput cloning applications, and allow simultaneous cloning into multiple vectors that feature various intracellular targeting destinations for the protein product. The ability to control expression and trafficking is intended to provide a rapid, rational approach to cancer therapy and emerging infectious diseases.
Collapse
Affiliation(s)
- James A Williams
- Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA.
| | | | | | | |
Collapse
|
40
|
González B, Reina R, García I, Andrés S, Glaria I, Alzueta M, Mora MI, Jugo BM, Arrieta-Aguirre I, de la Lastra JMP, Rodríguez D, Rodríguez JR, Esteban M, Grilló MJ, Blacklaws BA, Harkiss GD, Chebloune Y, Luján L, de Andrés D, Amorena B. Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection. Vaccine 2005; 23:4342-52. [PMID: 16005743 DOI: 10.1016/j.vaccine.2005.03.032] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2004] [Accepted: 03/16/2005] [Indexed: 11/23/2022]
Abstract
Gene gun mucosal DNA immunization of sheep with a plasmid expressing the env gene of Maedi-Visna virus (MVV) was used to examine the protection against MVV infection in sheep from a naturally infected flock. For immunization, sheep were primed with a pcDNA plasmid (pcDNA-env) encoding the Env glycoproteins of MVV and boosted with combined pcDNA-env and pCR3.1-IFN-gamma plasmid inoculations. The pcDNA plasmid used in the control group contained the lacZ coding sequences instead of the env gene. Within a month post-challenge, the viral load in the vaccinated group was lower (p < or = 0.05) and virus was only detected transiently compared with the control group. Furthermore, 2 months later, neutralizing antibodies (NtAb) were detected in all the control animals and none of the vaccinated animals (p < or = 0.01). These results demonstrated a significant early protective effect of this immunization strategy against MVV infection that restricts the virus replication following challenge in the absence of NtAb production. This vaccine protective effect against MVV infection disappeared after two years post-challenge, when active replication of MVV challenge strain was observed. Protection conferred by the vaccine could not be explained by OLA DRB1 allele or genotype differences. Most of the individuals were DRB1 heterozygous and none was totally resistant to infection.
Collapse
|
41
|
Liu L, Zhou X, Liu H, Xiang L, Yuan Z. CpG motif acts as a 'danger signal' and provides a T helper type 1-biased microenvironment for DNA vaccination. Immunology 2005; 115:223-30. [PMID: 15885128 PMCID: PMC1782151 DOI: 10.1111/j.1365-2567.2005.02150.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2004] [Revised: 02/03/2005] [Accepted: 02/04/2005] [Indexed: 11/29/2022] Open
Abstract
The method of delivering a DNA vaccine can influence the type of immune response induced by the vaccine. Application of a DNA vaccine by gene gun typically induces a T helper type 2 (Th2)-type reaction, whereas needle inoculation triggers a Th1 response. In the present study, we found that physical trauma, gold-particle bombardment and the CpG motif can act as 'danger signals' that recruit inflammatory cells to damaged tissues. Analysis of the cytokine profiles of draining lymph nodes or lymph-node-derived mononuclear cells from different groups by real-time reverse transcription-polymerase chain reaction revealed that, while gene-gun-bombardment induced a Th2-type cytokine microenvironment with increased interleukin-4 (IL-4) and IL-10 mRNA expression and almost no increase in IL-12 and interferon-gamma mRNA expression in draining lymph nodes, intradermal injection as well as subcutaneous injection of muscle induced the opposite. We further studied whether the addition of the CpG motif can switch the Th2-type cytokine microenvironment produced by gene-gun bombardment in draining lymph nodes. Results showed that the addition of the CpG motif can increase IL-12 mRNA expression in draining lymph nodes whether induced by intradermal injection, intramuscular injection, or gene-gun bombardment. These data suggest that delivery of the CpG motif induced a Th1-biased microenvironment in draining lymph nodes. Taken together, the CpG motif can act as a 'danger signal' and Th1 immune response enhancer in DNA vaccination. These results may help to explain the mechanism of different types of immune response induced by DNA vaccines delivered by different routes and facilitate the application of DNA vaccines.
Collapse
Affiliation(s)
- Ling Liu
- Key Laboratory of Medical Molecular Virology, Ministry of Education and Health, Shanghai Medical College, Fudan University, Shanghai, China
| | | | | | | | | |
Collapse
|
42
|
Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid Membrane Protein-11 DNA Vaccination Induces Complete Protection against Both Pentavalent Antimonial-Sensitive and -Resistant Strains ofLeishmania donovaniThat Correlates with Inducible Nitric Oxide Synthase Activity and IL-4 Generation: Evidence for Mixed Th1- and Th2-Like Responses in Visceral Leishmaniasis. THE JOURNAL OF IMMUNOLOGY 2005; 174:7160-71. [PMID: 15905560 DOI: 10.4049/jimmunol.174.11.7160] [Citation(s) in RCA: 199] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The emergence of an increasing number of Leishmania donovani strains resistant to pentavalent antimonials (SbV), the first line of treatment for visceral leishmaniasis worldwide, accounts for decreasing efficacy of chemotherapeutic interventions. A kinetoplastid membrane protein-11 (KMP-11)-encoding construct protected extremely susceptible golden hamsters from both pentavalent antimony responsive (AG83) and antimony resistant (GE1F8R) virulent L. donovani challenge. All the KMP-11 DNA vaccinated hamsters continued to survive beyond 8 mo postinfection, with the majority showing sterile protection. Vaccinated hamsters showed reversal of T cell anergy with functional IL-2 generation along with vigorous specific anti-KMP-11 CTL-like response. Cytokines known to influence Th1- and Th2-like immune responses hinted toward a complex immune modulation in the presence of a mixed Th1/Th2 response in conferring protection against visceral leishmaniasis. KMP-11 DNA vaccinated hamsters were protected by a surge in IFN-gamma, TNF-alpha, and IL-12 levels along with extreme down-regulation of IL-10. Surprisingly the prototype candidature of IL-4, known as a disease exacerbating cytokine, was found to have a positive correlation to protection. Contrary to some previous reports, inducible NO synthase was actively synthesized by macrophages of the protected hamsters with concomitant high levels of NO production. This is the first report of a vaccine conferring protection to both antimony responsive and resistant Leishmania strains reflecting several aspects of clinical visceral leishmaniasis.
Collapse
MESH Headings
- Animals
- Antibodies, Protozoan/biosynthesis
- Antigens, Protozoan/immunology
- Antimony/pharmacology
- Cell Line
- Cricetinae
- Cytotoxicity, Immunologic/immunology
- Drug Resistance/genetics
- Humans
- Immunoglobulin G/biosynthesis
- Interleukin-2/biosynthesis
- Interleukin-4/biosynthesis
- Leishmania donovani/genetics
- Leishmania donovani/immunology
- Leishmania donovani/pathogenicity
- Leishmaniasis, Visceral/immunology
- Leishmaniasis, Visceral/parasitology
- Leishmaniasis, Visceral/pathology
- Leishmaniasis, Visceral/prevention & control
- Liver Diseases, Parasitic/immunology
- Liver Diseases, Parasitic/parasitology
- Liver Diseases, Parasitic/pathology
- Liver Diseases, Parasitic/prevention & control
- Membrane Glycoproteins/administration & dosage
- Membrane Glycoproteins/genetics
- Membrane Glycoproteins/immunology
- Nitric Oxide Synthase/biosynthesis
- Nitric Oxide Synthase/genetics
- Nitric Oxide Synthase/metabolism
- Protozoan Proteins/administration & dosage
- Protozoan Proteins/genetics
- Protozoan Proteins/immunology
- Reactive Nitrogen Species/biosynthesis
- Reactive Oxygen Species/metabolism
- Spleen/cytology
- Spleen/immunology
- Spleen/metabolism
- Spleen/parasitology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/parasitology
- Th1 Cells/immunology
- Th1 Cells/metabolism
- Th1 Cells/parasitology
- Th2 Cells/immunology
- Th2 Cells/metabolism
- Th2 Cells/parasitology
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
Collapse
Affiliation(s)
- Rajatava Basu
- Department of Immunology, Indian Institute of Chemical Biology, Kolkata
| | | | | | | | | | | |
Collapse
|
43
|
Aasa-Chapman MMI, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P, McKnight A. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005; 79:2823-30. [PMID: 15709001 PMCID: PMC548453 DOI: 10.1128/jvi.79.5.2823-2830.2005] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Specific CD8 T-cell responses to human immunodeficiency virus type 1 (HIV-1) are induced in primary infection and make an important contribution to the control of early viral replication. The importance of neutralizing antibodies in containing primary viremia is questioned because they usually arise much later. Nevertheless antienvelope antibodies develop simultaneously with, or even before, peak viremia. We determined whether such antibodies might control viremia by complement-mediated inactivation (CMI). In each of seven patients studied, antibodies capable of CMI appeared at or shortly after the peak in viremia, concomitantly with detection of virus-specific T-cell responses. The CMI was effective on both autologous and heterologous HIV-1 isolates. Activation of the classical pathway and direct viral lysis were at least partly responsible. Since immunoglobulin G (IgG)-antibodies triggered the CMI, specific memory B cells could also be induced by vaccination. Thus, consideration should be given to vaccination strategies that induce IgG antibodies capable of CMI.
Collapse
Affiliation(s)
- Marlén M I Aasa-Chapman
- Windeyer Institute of Medical Sciences, Wohl Virion Centre, 46 Cleveland St., London W1T 4JF, United Kingdom
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Humans have a sophisticated immune system that functions to clear invading organisms and abnormal cells. However, cancers are able to arise despite this immune system. Vaccines have the potential of benefiting cancer patients by stimulating an immune response against tumor-associated antigens (TAA). Our enhanced understanding of how the immune system processes and presents antigens has allowed an array of vaccine modalities to be developed and tested. The TAA with the greatest number of vaccine platforms tested in colorectal cancer is carcinoembyronic antigen (CEA). Trials to date have demonstrated safety and evidence for the induction of an immune response against CEA. This article will review trials conducted with a variety of CEA vaccines. Most studies conducted are phase I or II in the metastatic disease setting, limiting our understanding of the role of the immune response in controlling colon cancers. Phase III trials conducted to date have conflicting data with respect to improvements in disease-free and overall survival. It is our challenge to determine if and which vaccines have sufficient benefit to warrant large-scale trials in the adjuvant and prevention settings.
Collapse
|
45
|
Smahel M, Pokorná D, Macková J, Vlasák J. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 2005; 6:1092-101. [PMID: 15386741 DOI: 10.1002/jgm.596] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Human papillomavirus type 16 (HPV16) E7 is an unstable oncoprotein with low immunogenicity. In previous work, we prepared the E7GGG gene containing point mutations resulting in substitution of three amino acids in the pRb-binding site of the HPV16 E7 protein. METHODS AND RESULTS To increase E7GGG immunogenicity we constructed fusion genes of E. coli beta-glucuronidase (GUS) with one or three copies of E7GGG. Furthermore, a similar construct was prepared with partial E7GGG (E7GGGp, 41 amino acids from the N-terminus). The expression of the fusion genes was examined in human 293T cells. Quantification of GUS activity and the amount of E7 antigen showed substantially reduced GUS activity of fusion proteins with complete E7GGG that was mainly caused by decrease of their steady-state level in comparison with GUS or E7GGGpGUS. Still, the steady-state level of E7GGG.GUS was about 20-fold higher than that of the E7GGG protein. The immunogenicity of the fusion genes with complete E7GGG was tested by DNA immunisation of C57BL/6 mice with a gene gun. TC-1 cells and their clone TC-1/A9 with down-regulated MHC class I expression were subcutaneously (s.c.) inoculated to induce tumour formation. All mice were protected against challenge with TC-1 cells and most animals remained tumour-free in therapeutic-immunisation experiments with these cells, in contrast to immunisation with unfused E7GGG and the fusion with the lysosome-associated membrane protein 1 (Sig/E7GGG/LAMP-1). Significant protection was also recorded against TC-1/A9 cells. Both tetramer staining and ELISPOT assay showed substantially higher activation of E7-specific CD8+ lymphocytes in comparison with E7GGG and Sig/E7GGG/LAMP-1. Deletion of 231 bp in the GUS gene eliminated enzymatic activity, but did not influence the immunogenicity of the E7GGG.GUS gene. CONCLUSIONS The findings demonstrate the superior immunisation efficacy of the fusion genes of E7GGG with GUS when compared with E7GGG and Sig/E7GGG/LAMP-1. The E7GGG.GUS-based DNA vaccine might also be efficient against human tumour cells with reduced MHC class I expression.
Collapse
Affiliation(s)
- Michal Smahel
- Institute of Hematology and Blood Transfusion, Department of Experimental Virology, Prague, Czech Republic.
| | | | | | | |
Collapse
|
46
|
Mayrhofer P, Tabrizi CA, Walcher P, Haidinger W, Jechlinger W, Lubitz W. Immobilization of plasmid DNA in bacterial ghosts. J Control Release 2005; 102:725-35. [PMID: 15681093 DOI: 10.1016/j.jconrel.2004.10.026] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2004] [Accepted: 10/21/2004] [Indexed: 11/20/2022]
Abstract
The development of novel delivery vehicles is crucial for the improvement of DNA vaccine efficiency. In this report, we describe a new platform technology, which is based on the immobilization of plasmid DNA in the cytoplasmic membrane of a bacterial carrier. This technology retains plasmid DNA (Self-Immobilizing Plasmid, pSIP) in the host envelope complex due to a specific protein/DNA interaction during and after protein E-mediated lysis. The resulting bacterial ghosts (empty bacterial envelopes) loaded with pDNA were analyzed in detail by real time PCR assays. We could verify that pSIP plasmids were retained in the pellets of lysed Escherichia coli cultures indicating that they are efficiently anchored in the inner membrane of bacterial ghosts. In contrast, a high percentage of control plasmids that lack essential features of the self-immobilization system were expelled in the culture broth during the lysis process. We believe that the combination of this plasmid immobilization procedure and the protein E-mediated lysis technology represents an efficient in vivo technique for the production of non-living DNA carrier vehicles. In conclusion, we present a "self-loading", non-living bacterial DNA delivery vector for vaccination endowed with intrinsic adjuvant properties of the Gram-negative bacterial cell envelope.
Collapse
Affiliation(s)
- Peter Mayrhofer
- Institute of Microbiology and Genetics, Section Microbiology and Biotechnology, University of Vienna, UZA II, 2B522, Althanstrasse 14, A-1090 Wien, Austria
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
DNA vaccines have been used to generate protective immunity against tumors in a variety of experimental models. The favorite target antigens have been those that are frequently expressed by human tumors, such as carcinoembryonic antigen (CEA), ErbB2/neu, and melanoma-associated antigens. DNA vaccines have the advantage of being simple to construct, produce and deliver. They can activate all arms of the immune system, and allow substantial flexibility in modifying the type of immune response generated through codelivery of cytokine genes. DNA vaccines can be applied by intramuscular, dermal/epidermal, oral, respiratory and other routes, and pose relatively few safety concerns. Compared to other nucleic acid vectors, they are usually devoid of viral or bacterial antigens and can be designed to deliver only the target tumor antigen(s). This is likely to be important when priming a response against weak tumor antigens. DNA vaccines have been more effective in rodents than in larger mammals or humans. However, a large number of methods that might be applied clinically have been shown to ameliorate these vaccines. This includes in vivo electroporation, and/or inclusion of various immunostimulatory molecules, xenoantigens (or their epitopes), antigen-cytokine fusion genes, agents that improve antigen uptake or presentation, and molecules that activate innate immunity mechanisms. In addition, CpG motifs carried by plasmids can overcome the negative effects of regulatory T cells. There have been few studies in humans, but recent clinical trials suggest that plasmid/virus, or plasmid/antigen-adjuvant, prime-boost strategies generate strong immune responses, and confirm the usefulness of plasmid-based vaccination.
Collapse
Affiliation(s)
- Gérald J Prud'homme
- Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital and University of Toronto, Ontario M5B 1W8, Canada.
| |
Collapse
|
48
|
Cohen AD, Wolchok JD. DNA vaccines for melanoma. ACTA ACUST UNITED AC 2005; 22:761-8. [PMID: 16110639 DOI: 10.1016/s0921-4410(04)22035-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Affiliation(s)
- Adam D Cohen
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
| | | |
Collapse
|
49
|
Yoshikawa T, Imazu S, Gao JQ, Hayashi K, Tsuda Y, Shimokawa M, Sugita T, Niwa T, Oda A, Akashi M, Tsutsumi Y, Mayumi T, Nakagawa S. Augmentation of antigen-specific immune responses using DNA-fusogenic liposome vaccine. Biochem Biophys Res Commun 2004; 325:500-5. [PMID: 15530420 DOI: 10.1016/j.bbrc.2004.10.056] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2004] [Indexed: 10/26/2022]
Abstract
In an attempt to enhance the immunological efficacy of genetic immunization, we investigated a new biological means for delivering antigen gene directly to the cytoplasm via membrane fusion. In this context, we investigated fusogenic liposome (FL) encapsulating DNA as a possible genetic immunization vehicle. RT-PCR analysis indicated that a FL could introduce and express encapsulating OVA gene efficiently and rapidly in vitro. Consistent with this observation, an in vitro assay showed that FL-mediated antigen-gene delivery can induce potent presentation of antigen via the MHC class I-dependent pathway. Accordingly, immunization with FL containing the OVA-gene induced potent OVA-specific Th1 and Th2 cytokine production. Additionally, OVA-specific CTL responses and antibody production were also observed in systemic compartments including the spleen, upon immunization with the OVA-gene encapsulating FL. These findings suggest that FL is an effective genetic immunization carrier system for the stimulation of antigen-specific immune responses against its encoding antigen.
Collapse
Affiliation(s)
- Tomoaki Yoshikawa
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Maue AC, Waters WR, Palmer MV, Whipple DL, Minion FC, Brown WC, Estes DM. CD80 and CD86, but not CD154, augment DNA vaccine-induced protection in experimental bovine tuberculosis. Vaccine 2004; 23:769-79. [PMID: 15542201 DOI: 10.1016/j.vaccine.2004.07.019] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2004] [Revised: 07/02/2004] [Accepted: 07/07/2004] [Indexed: 01/10/2023]
Abstract
DNA vaccination is known to elicit robust cellular and humoral responses to encoded antigen. The co-administration of costimulatory molecules CD80 (B7-1), CD86 (B7-2) and CD154 (CD40L) has been shown to enhance immune responses in several murine models. The role of specific costimulatory molecules in non-rodent species remains incompletely characterized. In these studies, we demonstrate that the co-administration of CD80 and CD86, but not CD154, to an existing candidate subunit DNA vaccine (ESAT-6) against bovine tuberculosis, enhances protection after aerosol challenge with virulent Mycobacterium bovis. Additionally, we have shown that vaccination with M. bovis BCG is protective against tuberculosis following aerosol challenge in cattle. Two independent trials were conducted in cattle to determine the adjuvant effect of encoded antigen + CD80/CD86 and directly compare the adjuvant activities of CD80/CD86 to those of CD154. Co-administration of either CD80/CD86 or CD154 enhanced ESAT-6-specific IFN-gamma responses as compared to animals vaccinated with ESAT-6 DNA alone. However, following aerosol challenge, only animals vaccinated with CD80/CD86 possessed decreased pathology of the lungs and associated lymph nodes, as measured by gross examination, radiographic lesion morphometry and bacterial recovery. Collectively, these results demonstrate that the co-administration of costimulatory molecules with a protective antigen target enhances bovine immune responses to DNA vaccination, and that CD80/CD86 is superior to CD154 in augmenting DNA vaccine-induced protection in experimental bovine tuberculosis.
Collapse
Affiliation(s)
- Alexander C Maue
- Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65211, USA
| | | | | | | | | | | | | |
Collapse
|